Biological considerations when comparing proton therapy with photon therapy.

Owing to the limited availability of data on the outcome of proton therapy, treatments are generally optimized based on broadly available data on photon-based treatments. However, the microscopic pattern of energy deposition of protons differs from that of photons, leading to a different biological effect. Consequently, proton therapy needs a correction factor (relative biological effectiveness) to relate proton doses to photon doses, and currently, a generic value is used. Moreover, the macroscopic distribution of dose in proton therapy differs compared with photon treatments. Although this may offer new opportunities to reduce dose to normal tissues, it raises the question whether data obtained from photon-based treatments offer sufficient information on dose-volume effects to optimally use unique features of protons. In addition, there are potential differences in late effects due to low doses of secondary radiation outside the volume irradiated by the primary beam. This article discusses the controversies associated with these 3 issues when comparing proton and photon therapy.

[1]  E. Pedroni,et al.  Secondary neutron dose during proton therapy using spot scanning. , 2002, International journal of radiation oncology, biology, physics.

[2]  H. Kampinga,et al.  Changes in expression of injury after irradiation of increasing volumes in rat lung. , 2007, International journal of radiation oncology, biology, physics.

[3]  J. Deasy,et al.  Radiation dose-volume effects in radiation-induced rectal injury. , 2010, International journal of radiation oncology, biology, physics.

[4]  J. Battista,et al.  In-field and out-of-field effects in partial volume lung irradiation in rodents: possible correlation between early dna damage and functional endpoints. , 2000, International journal of radiation oncology, biology, physics.

[5]  Issam El Naqa,et al.  Heart irradiation as a risk factor for radiation pneumonitis , 2011, Acta oncologica.

[6]  Uwe Schneider,et al.  Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. , 2002, International journal of radiation oncology, biology, physics.

[7]  R. Epstein,et al.  Radiotherapy-induced second cancers: are we doing enough to protect young patients? , 1997, European journal of cancer.

[8]  A. Vissink,et al.  Secondary radiation damage as the main cause for unexpected volume effects: a histopathologic study of the parotid gland. , 2006, International journal of radiation oncology, biology, physics.

[9]  A. Upton Radiation Hormesis: Data and Interpretations , 2001, Critical reviews in toxicology.

[10]  R. Stewart,et al.  Neutron scattered dose equivalent to a fetus from proton radiotherapy of the mother. , 2006, Medical physics.

[11]  M. Martel,et al.  Radiation dose-volume effects in the lung. , 2010, International journal of radiation oncology, biology, physics.

[12]  M Goitein,et al.  Calculation of normal tissue complication probability and dose-volume histogram reduction schemes for tissues with a critical element architecture. , 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  N. Aaronson,et al.  Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  W. Dörr,et al.  Second Primary Tumors after Radiotherapy for Malignancies Treatment-Related Parameters , 2002, Strahlentherapie und Onkologie.

[15]  S. Kvaløy,et al.  Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Harm Meertens,et al.  Radiation damage to the heart enhances early radiation-induced lung function loss. , 2005, Cancer research.

[17]  Peter van Luijk,et al.  Unexpected changes of rat cervical spinal cord tolerance caused by inhomogeneous dose distributions. , 2003, International journal of radiation oncology, biology, physics.

[18]  S. España,et al.  Clinical consequences of relative biological effectiveness variations in proton radiotherapy of the prostate, brain and liver , 2011, Physics in medicine and biology.

[19]  S Agosteo,et al.  Secondary neutron and photon dose in proton therapy. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[20]  Z. Liao,et al.  Spatial heterogeneity of the volume effect for radiation pneumonitis in mouse lung. , 1997, International journal of radiation oncology, biology, physics.

[21]  Brian Wang,et al.  Simulation of organ-specific patient effective dose due to secondary neutrons in proton radiation treatment , 2005, Physics in medicine and biology.

[22]  M. Moerland,et al.  Large cohort dose-volume response analysis of parotid gland function after radiotherapy: intensity-modulated versus conventional radiotherapy. , 2008, International journal of radiation oncology, biology, physics.

[23]  J. Deasy,et al.  Modeling radiation pneumonitis risk with clinical, dosimetric, and spatial parameters. , 2006, International journal of radiation oncology, biology, physics.

[24]  B. Modan,et al.  Tumors of the brain and nervous system after radiotherapy in childhood. , 1988, The New England journal of medicine.

[25]  R. Mohan,et al.  The risk of developing a second cancer after receiving craniospinal proton irradiation , 2009, Physics in medicine and biology.

[26]  R. Doll,et al.  Cancer risks attributable to low doses of ionizing radiation: Assessing what we really know , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[27]  M. Koizumi,et al.  Comparison of radiobiological effective depths in 65-MeV modulated proton beams. , 1997, British Journal of Cancer.

[28]  V A Semenenko,et al.  Lyman–Kutcher–Burman NTCP model parameters for radiation pneumonitis and xerostomia based on combined analysis of published clinical data , 2008, Physics in medicine and biology.

[29]  K. Trott Can we reduce the incidence of second primary malignancies occurring after radiotherapy , 2009 .

[30]  Leslie L Robison,et al.  Risk of selected subsequent carcinomas in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Harm Meertens,et al.  Volume effects and region-dependent radiosensitivity of the parotid gland. , 2005, International journal of radiation oncology, biology, physics.

[32]  D M Green,et al.  Bone sarcomas linked to radiotherapy and chemotherapy in children. , 1987, The New England journal of medicine.

[33]  D. Brenner,et al.  Secondary neutrons in clinical proton radiotherapy: a charged issue. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[34]  M. Tucker,et al.  Second cancers after medulloblastoma: population-based results from the United States and Sweden , 1997, Cancer Causes & Control.

[35]  A Ottolenghi,et al.  Long-term cardiac mortality after radiotherapy of breast cancer--application of the relative seriality model. , 1996, The British journal of radiology.

[36]  Thomas Bortfeld,et al.  Optimization of Beam Parameters and Treatment Planning for Intensity Modulated Proton Therapy , 2003, Technology in cancer research & treatment.

[37]  F. O. Hoffman,et al.  Radiation effectiveness factors for use in calculating probability of causation of radiogenic cancers. , 2005, Health physics.

[38]  H. Paganetti Range uncertainties in proton therapy and the role of Monte Carlo simulations , 2012, Physics in medicine and biology.

[39]  N Zamboglou,et al.  Predictive factors in radiotherapy for non-small cell lung cancer: present status. , 2001, Lung cancer.

[40]  J. Seco,et al.  Comparison of out-of-field photon doses in 6 MV IMRT and neutron doses in proton therapy for adult and pediatric patients , 2010, Physics in medicine and biology.

[41]  H. Paganetti,et al.  Risk of developing second cancer from neutron dose in proton therapy as function of field characteristics, organ, and patient age. , 2008, International journal of radiation oncology, biology, physics.

[42]  R. Fisher,et al.  Dose-volume histogram analysis as predictor of radiation pneumonitis in primary lung cancer patients treated with radiotherapy. , 2005, International Journal of Radiation Oncology, Biology, Physics.

[43]  R. Hoover,et al.  Solid cancers after bone marrow transplantation. , 1997, The New England journal of medicine.

[44]  U Oelfke,et al.  Measurements of relative biological effectiveness of the 70 MeV proton beam at TRIUMF using Chinese hamster V79 cells and the high-precision cell sorter assay. , 1996, Radiation research.

[45]  Johannes A Langendijk,et al.  The impact of heart irradiation on dose-volume effects in the rat lung. , 2007, International journal of radiation oncology, biology, physics.

[46]  A M Kellerer,et al.  The relative biological effectiveness of 160 MeV protons--II. Biological data and their interpretation in terms of microdosimetry. , 1978, International journal of radiation oncology, biology, physics.

[47]  Peter C Austin,et al.  Automated variable selection methods for logistic regression produced unstable models for predicting acute myocardial infarction mortality. , 2004, Journal of clinical epidemiology.

[48]  Andrew K. Lee,et al.  Risk of secondary malignant neoplasms from proton therapy and intensity-modulated x-ray therapy for early-stage prostate cancer. , 2009, International journal of radiation oncology, biology, physics.

[49]  M. Moerland,et al.  Scintigraphic assessment of early and late parotid gland function after radiotherapy for head-and-neck cancer: a prospective study of dose-volume response relationships. , 2004, International journal of radiation oncology, biology, physics.

[50]  A. Nagano,et al.  Dilemmas concerning dose distribution and the influence of relative biological effect in proton beam therapy of medulloblastoma. , 2012, The British journal of radiology.

[51]  Joos V Lebesque,et al.  Regional differences in lung radiosensitivity after radiotherapy for non-small-cell lung cancer. , 2004, International journal of radiation oncology, biology, physics.

[52]  J. Habbema,et al.  Equally valid models gave divergent predictions for mortality in acute myocardial infarction patients in a comparison of logical regression models , 2005 .

[53]  M. Tubiana Can we reduce the incidence of second primary malignancies occurring after radiotherapy? A critical review. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[54]  Torunn I Yock,et al.  Assessment of radiation-induced second cancer risks in proton therapy and IMRT for organs inside the primary radiation field , 2012, Physics in medicine and biology.

[55]  L. Gerweck,et al.  Relative biological effectiveness of proton beams in clinical therapy. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[56]  Simon Bouffler,et al.  Assessing cancer risks of low-dose radiation , 2009, Nature Reviews Cancer.

[57]  E Grusell,et al.  Relative biological effectiveness of intermediate energy protons. Comparisons with 60Co gamma-radiation using two cell lines. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[58]  H. Paganetti,et al.  Neutron equivalent doses and associated lifetime cancer incidence risks for head & neck and spinal proton therapy , 2009, Physics in medicine and biology.

[59]  F. Ianzini,et al.  Mutation induction and RBE-LET relationship of low-energy protons in V79 cells. , 1991, International journal of radiation biology.

[60]  S. Webb,et al.  Novel approaches to improve the therapeutic index of head and neck radiotherapy: an analysis of data from the PARSPORT randomised phase III trial. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[61]  Yan Liu,et al.  New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. , 2006, Journal of the National Cancer Institute.

[62]  D. Goodhead Radiation effects in living cells , 1990 .

[63]  P. Maguire,et al.  73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  Uwe Oelfke,et al.  Proton versus photon radiotherapy for common pediatric brain tumors: Comparison of models of dose characteristics and their relationship to cognitive function , 2008, Pediatric blood & cancer.

[65]  J. Hopewell,et al.  Fractionation effects in particle radiotherapy: implications for hypo-fractionation regimes , 2010, Physics in medicine and biology.

[66]  Anatoly Rosenfeld,et al.  Assessment of out-of-field absorbed dose and equivalent dose in proton fields. , 2009, Medical physics.

[67]  J. Van Dyk,et al.  Partial volume rat lung irradiation: an evaluation of early DNA damage. , 1998, International journal of radiation oncology, biology, physics.

[68]  I. Yeung,et al.  Partial volume rat lung irradiation; assessment of early DNA damage in different lung regions and effect of radical scavengers. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[69]  A J Lomax,et al.  A treatment planning inter-comparison of proton and intensity modulated photon radiotherapy. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[70]  J. Fowler,et al.  Predicting realistic RBE values for clinically relevant radiotherapy schedules. , 1997, International journal of radiation biology.

[71]  Deasy Jo,et al.  Comments on the use of the Lyman-Kutcher-Burman model to describe tissue response to nonuniform irradiation. , 2000 .

[72]  E. Benton,et al.  Leakage and scatter radiation from a double scattering based proton beamline. , 2007, Medical physics.

[73]  D. Fairclough,et al.  Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  Icru Prescribing, recording, and reporting photon beam therapy , 1993 .

[75]  A. Niemierko,et al.  Projected second tumor risk and dose to neurocognitive structures after proton versus photon radiotherapy for benign meningioma. , 2012, International journal of radiation oncology, biology, physics.

[76]  A. Niemierko,et al.  Modeling of normal tissue response to radiation: the critical volume model. , 1993, International journal of radiation oncology, biology, physics.

[77]  J. Little,et al.  Radiobiological studies of a high‐energy modulated proton beam utilizing cultured mammalian cells , 1975 .

[78]  Kurt Baier,et al.  Dose, volume, and tumor control prediction in primary radiotherapy of non-small-cell lung cancer. , 2002, International journal of radiation oncology, biology, physics.

[79]  Harald Paganetti,et al.  Relative biological effectiveness (RBE) values for proton beam therapy. , 2002, International journal of radiation oncology, biology, physics.

[80]  E. Hall,et al.  The relative biological effectiveness of 160 MeV protons , 1978 .

[81]  E. Hall,et al.  Intensity-modulated radiation therapy, protons, and the risk of second cancers. , 2006, International journal of radiation oncology, biology, physics.

[82]  J. Lyman Complication Probability as Assessed from Dose-Volume Histograms , 1985 .

[83]  P. van Luijk,et al.  Regional differences in radiosensitivity across the rat cervical spinal cord. , 2005, International journal of radiation oncology, biology, physics.

[84]  J. Deasy,et al.  Multivariable modeling of radiotherapy outcomes, including dose-volume and clinical factors. , 2006, International journal of radiation oncology, biology, physics.

[85]  Anatoly Rosenfeld,et al.  Out-of-field dose equivalents delivered by passively scattered therapeutic proton beams for clinically relevant field configurations. , 2008, International journal of radiation oncology, biology, physics.

[86]  J A Purdy,et al.  Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC) , 1999, International journal of radiation oncology, biology, physics.

[87]  Andrew Jackson,et al.  Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study. , 2004, International journal of radiation oncology, biology, physics.

[88]  Harald Paganetti,et al.  Assessment of organ-specific neutron equivalent doses in proton therapy using computational whole-body age-dependent voxel phantoms , 2008, Physics in medicine and biology.

[89]  P. van Luijk,et al.  Data on dose-volume effects in the rat spinal cord do not support existing NTCP models. , 2005, International journal of radiation oncology, biology, physics.

[90]  Harald Paganetti,et al.  Variations in linear energy transfer within clinical proton therapy fields and the potential for biological treatment planning. , 2011, International journal of radiation oncology, biology, physics.

[91]  Anatoly Rosenfeld,et al.  Out-of-field dose equivalents delivered by proton therapy of prostate cancer. , 2007, Medical physics.

[92]  H. Paganetti,et al.  Comparison of second cancer risk due to out-of-field doses from 6-MV IMRT and proton therapy based on 6 pediatric patient treatment plans. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[93]  Marilyn Stovall,et al.  Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  A. Koehler,et al.  Measurement of neutron dose equivalent to proton therapy patients outside of the proton radiation field , 2002 .

[95]  A. Lomax,et al.  Helical tomotherapy vs. intensity-modulated proton therapy for whole pelvis irradiation in high-risk prostate cancer patients: dosimetric, normal tissue complication probability, and generalized equivalent uniform dose analysis. , 2011, International journal of radiation oncology, biology, physics.

[96]  R. Marchesini,et al.  Radiobiological studies on the 65 MeV therapeutic proton beam at Nice using human tumour cells. , 2000, International journal of radiation biology.

[97]  X. Xu,et al.  Better radiation weighting factors for neutrons generated from proton treatment are needed. , 2010, Radiation protection dosimetry.

[98]  S. Bentzen Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology , 2006, Nature Reviews Cancer.

[99]  M. Goitein,et al.  The general relation between tissue response to x-radiation (α/β-values) and the relative biological effectiveness (RBE) of protons: Prediction by the Katz track-structure model , 2000 .

[100]  U. Schneider,et al.  Site-specific dose-response relationships for cancer induction from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy , 2011, Theoretical Biology and Medical Modelling.

[101]  Yan Liu,et al.  Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study , 2005, The Lancet.

[102]  R. Mohan,et al.  Monte Carlo study of neutron dose equivalent during passive scattering proton therapy , 2007, Physics in medicine and biology.

[103]  Jean Chavaudra,et al.  Frequency distribution of second solid cancer locations in relation to the irradiated volume among 115 patients treated for childhood cancer. , 2009, International journal of radiation oncology, biology, physics.

[104]  A Brahme,et al.  Tumour and normal tissue responses to fractionated non-uniform dose delivery. , 1992, International journal of radiation biology.

[105]  Damien C Weber,et al.  A treatment planning comparison of intensity modulated photon and proton therapy for paraspinal sarcomas. , 2003, International journal of radiation oncology, biology, physics.

[106]  H Paganetti,et al.  Elevated LET components in clinical proton beams , 2011, Physics in medicine and biology.

[107]  F. Ballarini,et al.  Cellular communication and bystander effects: a critical review for modelling low-dose radiation action. , 2002, Mutation research.

[108]  T. Bortfeld,et al.  Neutron dose in proton radiation therapy: in regard to Eric J. Hall (Int J Radiat Oncol Biol Phys 2006;65:1-7). , 2006, International journal of radiation oncology, biology, physics.

[109]  Marco Durante,et al.  Charged particles in radiation oncology , 2010, Nature Reviews Clinical Oncology.

[110]  Johannes A Langendijk,et al.  Bath and shower effects in the rat parotid gland explain increased relative risk of parotid gland dysfunction after intensity-modulated radiotherapy. , 2009, International journal of radiation oncology, biology, physics.

[111]  S. Brandenburg,et al.  Volume-dependent expression of in-field and out-of-field effects in the proton-irradiated rat lung. , 2011, International journal of radiation oncology, biology, physics.

[112]  T. Sakae,et al.  Measurement of neutron ambient dose equivalent in passive carbon-ion and proton radiotherapies. , 2008, Medical physics.

[113]  C. Rubino,et al.  Radiation dose and risk of soft tissue and bone sarcoma after breast cancer treatment , 2005, Breast Cancer Research and Treatment.

[114]  Joseph O Deasy,et al.  Radiotherapy dose-volume effects on salivary gland function. , 2010, International journal of radiation oncology, biology, physics.

[115]  B. Gottschalk Neutron dose in scattered and scanned proton beams: in regard to Eric J. Hall (Int J Radiat Oncol Biol Phys 2006;65:1-7). , 2006, International journal of radiation oncology, biology, physics.

[116]  Randall K Ten Haken,et al.  Parotid gland function after radiotherapy: the combined michigan and utrecht experience. , 2008, International journal of radiation oncology, biology, physics.

[117]  J. Thacker,et al.  Mutation and inactivation of cultured mammalian cells exposed to beams of accelerated heavy ions. II. Chinese hamster V79 cells. , 1979, International journal of radiation biology and related studies in physics, chemistry, and medicine.

[118]  Rick Chappell,et al.  Is α/β for prostate tumors really low? , 2001 .